Matt DeLisa
Directeur/Membre du Conseil chez Versatope Therapeutics, Inc.
Postes actifs de Matt DeLisa
Sociétés | Poste | Début | Fin |
---|---|---|---|
Versatope Therapeutics, Inc.
Versatope Therapeutics, Inc. BiotechnologyHealth Technology Versatope Therapeutics, Inc. is an immuno-therapeutic company based in Lowell, MA. The private company harnesses a customized biotechnology platform to deliver immunity using state-of-the-art synthetic biology and bioinformatics. The company customizes exosome-like vesicles made from probiotics to display targets in a 3D context that activates potent immunity. The company's lead vaccine candidate addresses the need for improved, effective universal influenza vaccines to prevent influenza and other emerging infectious diseases, such as the current COVID-19. The company was founded in 2017 by Christopher Locher and Dave Putnam, and Christopher Locher has been the CEO since 2017. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Matt DeLisa
Statistiques
Internationale
Etats-Unis | 2 |
Opérationnelle
Director/Board Member | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Versatope Therapeutics, Inc.
Versatope Therapeutics, Inc. BiotechnologyHealth Technology Versatope Therapeutics, Inc. is an immuno-therapeutic company based in Lowell, MA. The private company harnesses a customized biotechnology platform to deliver immunity using state-of-the-art synthetic biology and bioinformatics. The company customizes exosome-like vesicles made from probiotics to display targets in a 3D context that activates potent immunity. The company's lead vaccine candidate addresses the need for improved, effective universal influenza vaccines to prevent influenza and other emerging infectious diseases, such as the current COVID-19. The company was founded in 2017 by Christopher Locher and Dave Putnam, and Christopher Locher has been the CEO since 2017. | Health Technology |
- Bourse
- Insiders
- Matt DeLisa
- Expérience